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Abstract
Background: Amlexanox has been developed as a 5 percent topical oral paste for the treatment of patients with
recurrent aphthous stomatitis (RAS) in most European countries. However, it is not yet available in China and has not
been generally accepted in clinical treatment. The aim of this study was to explore the effectiveness of amlexanox oral
adhesive pellicles in the treatment of minor recurrent aphthous ulcers, and compare the results with those of amlexanox
oral adhesive tablets in order to analyse the difference between the two dosage forms of amlexanox.
Methods: We performed a randomized, blinded, placebo-controlled, parallel, multicenter clinical study. A total of 216
patients with minor recurrent aphthous ulcers (MiRAU) were recruited and randomized to amlexanox pellicles or
placebo pellicles. Pellicles were consecutively applied four times per day, for five days. The size and pain level of ulcers
were measured and recorded on treatment days 0, 4 and 6. Finally, the results were compared with those of our previous
104 cases treated with amlexanox tablets.
Results: Amlexanox oral adhesive pellicles significantly reduced ulcer size (P= 0.017 for day 4, P=0.038 for day 6) and
alleviated ulcer pain (P=0.021 for day 4, P=0.036 for day 6). No significant difference was observed in the treatment
effectiveness between the pellicle and tablet form of amlexanox.
Conclusions: Amlexanox oral adhesive pellicles are as effective and safe as amlexanox oral adhesive tablets in the
treatment of MiRAU for this Chinese cohort. However, pellicles seem to be more comfortable to use when compared
with the dosage form of tablets. Therefore, in clinical practice, amlexanox oral adhesive pellicles may be a better choice
for RAS patients.
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Introduction
Recurrent aphthous stomatitis (RAS) is one of the most
common oral mucosa diseases. It can affect both men and
women of all ages, races and geographic regions. Minor
Recurrent aphthous ulceration (MiRAU) is the most com-
mon form, which accounts for approximately 70% to
87% of the population with RAS [1,2] and usually has 1
to 5 ulcers at one episode, with each ulcer varying from 3
to 10 mm [3]. For RAS patients, the ulcer pain associated
with each episode may severely interfere with eating,
speaking, and swallowing.
Although RAS represents a very common oral lesion, its
etiology is unknown. Some studies [4,5] have showed that
several local and system factors, such as local trauma,
immunodeficiency, Haematinic or zinc deficiency and
hormonal changes may play a role in the pathogenesis of
RAS. Suspected bacteria and viruses may also associate
with RAS [6]. Since the etiology is unknown, no curative
therapy is available at present. All available systemic or
topical treatment methods nowadays are to relieve symp-
tom and accelerate healing. Most systemic medications,
although effective, have side effects that limit their general
use. Therefore, topical agents remain the first choice for
the treatment of RAS, due to their effectiveness and safety.
Amlexanox (C16H14N2O4) is a topical anti-inflammatory,
anti-allergic drug. It has been developed as a 5% topical
oral paste for the treatment of patients with RAS [7-9] and
is currently the only clinically proven product approved
by the US FDA for the treatment of aphthous ulcers [10].
However, it is not available in China yet. In our previous
clinical trial [11], we have demonstrated that amlexanox
oral adhesive tablets (active component is 2 mg amlex-
anox) are effective in the treatment of RAS without major
side effects recorded, which were consistent with the pre-
vious trials [8,9]. However, during that study, we noticed
that some patients complained about the lack of adher-
ence of amlexanox adhesive tablets in some fricative areas
and the obvious feeling of extraneous material which
made them quite uncomfortable. To solve these prob-
lems, another form of amlexanox–oral adhesive pellicles
was developed and studied in this randomized, blinded,
placebo controlled, parallel, multicentre clinical trial. The
amlexanox pellicles contained the same ingredients as the
amlexanox tablets, with carrier material being the only
difference.
The aims of this study are to evaluate the effectiveness and
safety of amlexanox oral adhesive pellicles in the treat-
ment of MiRAU and to compare the results of amlexanox
oral adhesive pellicles with our previous data [11] on aml-
exanox adhesive tablets to analyze the effectiveness,
safety, comfort, and convenience of these two amlexanox
forms. The study design, assessment criteria and analysis
method of our current and previous studies were exactly
the same.
Methods and materials
Study design
The study was a randomized, blinded, placebo controlled,
parallel, multicentre, clinical design. The protocol was
reviewed by the Institutional Ethics Committee (IEC)/
Institutional Review Board (IRB) of Sichuan University,
and each subject signed a detailed informed consent form.
All patients were instructed to apply one pellicle to that
identified ulcer 4 times a day (after meals and before bed-
time) for 5 days (day 1 to day 5). The baseline parameters
were taken and recorded on the day of the first visit. Effec-
tiveness and safety evaluations were made on the morning
of Day 4 visit and Day 6 visit.
Blinding
The patients with MiRAU were assigned to treatment
group (amlexanox adhesive pellicles) or placebo group by
using a computer-generated random number list. The
treatment and the placebo agents were packed in identical
looking containers and labeled with a code number A or
B randomly (named agents A and B) by a statistician from
Peking Union Medical College. The code record was kept
in Beijing Fu Rei Kang Zheng Medical and Pharmaceutical
Institute. Participants assigned to the treatment A received
agents A while those assigned to treatment B received
agents B. All the investigators/evaluators and patients who
participated were blinded to the treatment and placebo
agents.
Methods
The index ulcer's size were measured by using a similar
methodology as described before [11] on treatment Days
0, 4 and 6. The investigators measured the maximum and
minimum diameters when the ulcer had an oval shape,
using a calibrated dental probe with millimeter markings.
The two measurements were then multiplied to represent
the cross-sectional areas of the ulcer.
To evaluate pain, a visual analog scale (VAS) consisting of
a 10-cm horizontal line between poles connoting no pain
(origin) to unbearable pain was used. Subjects were told
to mark the line with a vertical line at the point that best
represented the present pain level of the ulcer.
The effectiveness indics (EI) of the ulcer size and pain
improvement were calculated with the following formula
(V4 and V6 referring to the values measured at Day 4 visit
and Day 6 visit, while V1 referring to the baseline value
measured before the study entry): EI = [(V1 – V4 or V6) ÷
V1] × 100%. The effectiveness indices were evaluated on aTrials 2009, 10:30 http://www.trialsjournal.com/content/10/1/30
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4-rank scale: (1) Heal: EI ≥ 95%; (2) Marked improve-
ment: EI<95%, but ≥ 70%; (3) Moderate improvement:
EI<70%, but ≥ 30%; (4) No improvement: EI <30%.
All subjects were monitored on the day of the first visit
(Day 0) and the end of the study (Day 6) for the occur-
rence of potential laboratory abnormalities. The evalua-
tions included the following indices: complete blood cell
count with differential and platelet count; Alanine Ami-
notransferase (ALT); Aspartate Aminotransferase (AST);
Blood urea nitrogen (BUN); Creatinine (Cr). All the urine
and serum tests were performed at the site-specific labs in
each center.
Two doctors in Oral Medicine with at least 5 years of
expertise from each of the dental faculties were chosen as
evaluators in their respective centers, and were especially
trained by the main researcher at their institutions to
standardize clinical diagnosis and data collection.
Materials
Amlexanox is 2-amino-7-isopropyl-5-oxo-5H-(1) benzo-
pyrano-(2, 3-b) – pyridine-3- carboxylic acid. Amlexanox
adhesive pellicles are lamellar with white color and con-
tain 2 mg amlexanox (identical to the Food and Drug
Administration-approved drug in USA for the treatment
of canker sores, OraDisc A) with the following ingredi-
ents: carboxymethy1 cellulose (CMC),
hydroxypropylmethy1 cellulose (HPMC), carbomer, and
magnesium stearate. The placebo pellicles contain the
above-mentioned excipients except for the active ingredi-
ent (amlexanox). The dose and formulation have been
approved by the SFDA (State Food and Drug Administra-
tion) in China.
Patient group
All the clinical patients were recruited by advertising in the
general population at the study sites or from the clinical
patients of the participation centers, with identical inclu-
sion and exclusion criteria (Appendix).
To compare the effectiveness, safety of oral adhesive pelli-
cles with those of another dosage form of amlexanox, the
amlexanox oral adhesive tablets, the results of 108 sub-
jects treated with pellicles in this clinical trial were com-
pared with the 104 subjects treated with tablets in our
previous study [11]. Furthermore, 21 subjects who had
enrolled in both above-mentioned clinical trials were
requested to take a questionnaire to subjectively evaluate
the comfort and convenience of both dosage forms of
amlexanox.
Statistical analysis
Background and medical history data were summarized
with descriptive statistics, and a sample size of 216 sub-
jects were calculated by using an alpha error of 0.05 and
beta of 0.1. The t-test was performed to compare continu-
ous variables, while the chi-squared test to compare cate-
gorical variables. According to the data distribution,
Mann-Whitney  U  test was used in the comparison of
group differences between the amlexanox and placebo
controlled group on Day 4 and Day 6 visit. To evaluate the
effectiveness, the Chi-square test and the Mann-Whitney
U test were used. All data were analyzed by Peking Union
Medical College using SPSS software (SPSS 12.0 for Win-
dows; SPSS Inc., Chicago, III). P < 0.05 was considered
statistically significant.
Results
Demographics
A total of 216 subjects were enrolled in this study, with
140 at center 1 (West China College of Stomatology,
Sichuan University), 34 at center 2 (Hospital of Stomatol-
ogy, Chongqing University of Medical Sciences), and 42 at
center 3 (Hospital of Stomatology, Tianjin City). Among
all the 216 subjects, 21 subjects also participated our pre-
vious study [11]. Only 1 subject of the amlexanox group
and 2 subjects of the placebo controlled group were
excluded for not following the instructions by the doctor.
Therefore, 213 subjects (108 subjects in the amlexanox
group and 105 subjects in the placebo controlled group)
fulfilled the study. As the discontinuation rate (1.38%)
was quite low, we evaluated demographic and effective-
ness data without these 3 subjects, which made no influ-
ence on any of the interpretation or conclusions.
By the blinded randomization procedures, the amlexanox
group and the placebo controlled group were similar as to
demography including age, sex, medical history, known
allergies, and baseline values of ulcer history, size, and
pain (Additional file 1). No abnormal laboratory values
were found at study entry between the two groups.
Amlexanox significantly reduced the size of the ulcers
Ulcer size between the amlexanox and placebo controlled
group was significantly different at the Day 4 and Day 6
visit, respectively (P = 0.017, P = 0.038; Figure 1).
At the Day 4 visit, the effectiveness index of the amlexanox
group was much greater than that of the placebo control-
led group (P < 0.001). The amlexanox group had a statis-
tically significant higher "improvement" rate (66.67% vs
43.81%, P < 0.001), as well as a significantly higher
"marked improvement" rate (41.67% vs 17.14%, P <
0.001) when compared with that of the placebo control-
led group (Additional file 2).
At the Day 6 visit, compared with those of the placebo
controlled group, the amlexanox group maintained a sig-
nificantly greater effectiveness index (P < 0.001), theTrials 2009, 10:30 http://www.trialsjournal.com/content/10/1/30
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"improvement" rate (86.11% vs 63.81%, P < 0.001), and
"marked improvement" rate (73.15% vs 50.48%, P <
0.001; Additional file 2).
Amlexanox significantly moderated the pain of the ulcers
Similar results were observed in the ulcer pain resolution
between the two groups at the Day 4 and Day 6 visit (P =
0.019, P = 0.036, Figure 2).
At the Day 4 visit, the effectiveness index of the amlexanox
group was much greater than that of the placebo control-
led group (P = 0.001). The amlexanox group had a signif-
icantly higher "improvement" rate (78.70% vs 60.95%, P
= 0.005), as well as a significantly higher "marked
improvement" rate (41.67% vs 26.67%, P = 0.021) when
compared with that of the placebo controlled group.
At the Day 6 visit, compared with those of the placebo
controlled group, the amlexanox group still presented
with a significantly greater effectiveness index (P < 0.001),
the "improvement" rate (91.67% vs 73.33%, P < 0.001),
and "marked improvement" rate (75.00% vs 54.29%, P =
0.002; Additional file 3).
Safety evaluation
None of the patients in the study was observed or reported
to have any adverse reactions. None of the hematologic
values were considered clinically abnormal. There were no
laboratory differences between the 2 groups at baseline or
Day 6, and there were no significant changes over time.
Comparison of amlexanox oral adhesive pellicles and 
amlexanox adhesive tablets
As the data of the oral adhesive pellicles and amlexanox
adhesive tablets were obtained in the same centers, the
study design, experimental methods and assessment crite-
ria were the same, and the studies used for the comparison
were carried out within a limited time window, we com-
pared the results of the two amlexanox's group by using
the historical control method [12-15].
Just as demonstrated in Additional file 4, the amlexanox
oral adhesive pellicles had the similar effectiveness in
ulcer healing compared with that of the tablets. The
"improvement" rate of the two Amlexanox's forms in
both ulcer size reduction and ulcer pain moderation
showed no statistical significance on the follow-up Day 4
visit (P = 0.625, P = 0.580) and Day 6 visit (P = 0.758, P =
0.467). Moreover, No significant difference was obtained
in the "marked improvement" rate in ulcer size reduction
(P = 0.962, P = 0.758), as well as in ulcer pain moderation
(P = 0.425, P = 0.053) on Day 4 and Day 6 visit, respec-
tively.
The statistical results about the questionnaire demon-
strated that amlexanox oral pellicles didn't show much
difference in convenience as compared with amlexanox
oral adhesive tablets (P = 0.528). However, a significant
difference in comfort between both groups was obtained
(P = 0.001), with the amlexanox oral pellicles were evi-
dently better than the amlexanox oral adhesive tablets
(Additional file 5).
Discussion
The topical agents have been used for improving discom-
fort caused by RAS, including glucocorticoids, local anal-
gesics, anti-microbial mouthwash [16] and topical paste
such as 5% amlexanox [4]. Amlexanox is an anti-allergic
The comparison of ulcer size between amlexanox group and  placebo controlled group during follow-up Figure 1
The comparison of ulcer size between amlexanox 
group and placebo controlled group during follow-up. 
*Mean ulcer size in the amlexanox group was significantly 
smaller compared with that of the placebo group, Mann-
whitney U test. P* = 0.017; P** = 0.038.
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The comparison of ulcer pain moderation between amlex- anox group and placebo controlled group during follow-up  reported by all patients' Figure 2
The comparison of ulcer pain moderation between 
amlexanox group and placebo controlled group dur-
ing follow-up reported by all patients'. *Mean pain 
score in the amlexanox group was significantly smaller com-
pared with that of the placebo group, Mann-whitney U test. P 
* = 0.019; P** = 0.03.
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and anti-inflammatory agent which can inhibit the forma-
tion and release of histamine and leukotrienes from mast
cells, neutrophils, and mononuclear cells, possibly
through increasing intracellular cyclic AMP content in
inflammatory cells, and a membrane-stabilizing effect or
inhibition of calcium influx [17]. The therapeutic effect of
5% amlexanox for RAS has been reported in Caucasian in
a series of robust clinical trial programs [10,18].
Our present study has demonstrated that the 5% amlex-
anox oral adhesive pellicles could not only reduce the
ulcer size but also resolve the pain of the patients during
the RAS treatment lasting for 5 days in a placebo control-
led, randomized, blinded, multicentre clinical trial com-
prising of 213 subjects. The results showed that 86.11% of
subjects had significant improvement in ulcer size reduc-
tion (EI = 62.79%) vs. 63.81% of those using the placebo
(EI = 6.47%) on Day 6 visit. Data of improvement rate in
ulcer pain moderation of amlexanox group were 91.67%
(EI = 80.88%) vs. 73.33% (EI = 58.80%) of those in the
placebo controlled group on Day 6 visit. During the fol-
low-up, none of the study centers has reported any of sys-
temic side effects. All the results in our present study are
consistent with those from the previous trials[8-11],
although their dosage forms of amlexanox were different
from ours.
Interestingly, during the trial, we noted that the difference
in the mean ulcer size reduction on Day 6 visit (P = 0.038)
tended to be less significant than that on Day 4 visit (P =
0.017) between the amlexanox group and placebo group,
as well as in the ulcer pain moderation (P = 0.036 for Day
6, P = 0.021 for Day 4). These phenomena may be due to
the fact that these ulcers can usually resolve without any
treatment within 7–10 days based on this disease's natural
history, as well as the protective effects of the placebo
adhesive pellicle in covering the wound [7,8]. Therefore,
it is reasonable to prospect that the pain relief and ulcer
size reduction are more effective at the early stage at the
onset of RAS for the amlexanox treatment.
In our previous study, we have found that amlexanox oral
adhesive tablets were also effective in the treatment of
MiRAU in Chinese cohort. However, according to
patients' reflection of discomfort about amlexanox tab-
lets, we improved another dosage form of amlexanox,
amlexanox oral adhesive pellicles, and also evaluated
their effectiveness and safety in ulcer treatment. As a
result, the adhesive pellicles not only had the same effec-
tiveness and safety but also had better comfort when com-
pared with tablets.
As the adhesive pellicles are thinner and glutinous, they
can adhere to the mucosa surface more easily than the tab-
lets, which limit the likelihood that the drug will be
rubbed away or rinsed away with saliva flow. Further-
more, the extraneous material feeling of amlexanox pelli-
cles was gentler compared with the tablets according to
the patients' remarks. These may be the reasons that oral
adhesive pellicles are more comfortable to use than tab-
lets.
Limitations
In this study, we have noticed that baseline ulcer size in
the placebo-controlled group is larger than amlexanox
group as listed in Additional file 1. This may influence the
results of comparison between the two groups. However,
after controlling for the apparent imbalance between the
two groups at baseline there was no change in the overall
results. Studies on a larger number of subjects may be
needed to further confirm the results.
Conclusion
Amlexanox oral adhesive pellicles significantly reduced
ulcer size (P = 0.017 for Day 4, P = 0.038 for Day 6) and
alleviated ulcer pain (P = 0.021 for Day 4, P = 0.036 for
Day 6). No significant difference was observed in the
treatment effectiveness between the pellicle and tablet
form of amlexanox. So amlexanox oral adhesive pellicles
is as effective and safe as amlexanox oral adhesive tablets
in the treatment of MiRAU for this Chinese cohort. How-
ever, it seems to be more comfortable to use pellicles
when compared with the dosage form of tablets. There-
fore, in clinical practice, amlexanox oral adhesive pellicles
may be a better choice for the RAS patients.
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Appendix: selection criteria
Inclusion criteria:
1. Males and females aged 18–60 years old
2. Willingness to participate and sign the informed con-
sent forms
3. Presenting with 1 to 5 aphthous ulcers (less than 72
hours' duration) with a size no greater than 5 mm in
diameter
4. An expectation that their ulcers normally take 5 or more
days to resolve without treatment
5. Normal sense of pain, without anesthesia or paresthesia
Exclusion criteria:
1. A known history of serious drug hypersensitivities
2. Pregnancy and lactation (Urine hCG-positive)
3. Concurrent clinical conditions that could pose a health
risk to the subjects, including serious liver, kidney, and
heart dysfunctions
4. A history of an immunologic problem
5. Ulcers as a manifestation of a systemic disease process
such as ulcerative colitis, Crohn's disease, Behcet's syn-
drome, or serious anemia
6. Treatment with systemic steroid or other immunomod-
ulatory agents within 1 month before the study entry
7. Use of nonsteroidal anti-inflamatory drugs or oral anti-
histamines within 1 month prior to the study entry
8. Treatment of the ulcer with any preparation or medica-
tion within 72 hours prior to the study entry
9. Treatment with systemic antibiotics within 2 weeks
prior to the study entry
10. Attendance of any other clinical trials within 3 months
prior to the study entry
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